Example: stock market
Prior authorization and step therapy coverage criteria
1. Diagnosis of Still’s disease, including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) 2. Age ≥ 2 years old . 3. Trial and treatment failure of one of the following therapies: methotrexate, leflunomide, glucocorticoids, NSAIDs . OR . 1. Diagnosis of giant cell arteritis 2. Age ≥ 18 years old
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Blue Cross Complete Clinical Practice Guideline Summary
www.bcbsm.comBlue Cross Complete Clinical Practice Guideline Summary Guideline for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) Title: Blue Cross Complete Clinical Practice Guideline Summary Subject: Blue Cross Complete Clinical Practice Guideline Summary
Durable Medical Equipment/ Prosthetic and …
www.bcbsm.comDurable Medical Equipment/ Prosthetic and Orthotic Supplier Provider Participation Agreement
Prescription Drug Reimbursement Claim Form - …
www.bcbsm.comHealth Insurance Marketplace Prescription Drug Reimbursement Claim Form é Instructions: Please read carefully or claims may be returned. Save time and money. In the future, present your BCBSM ID card at a participating pharmacy and ask them to submit your prescription
Tip Sheet Mental Health and Behavioral Health - …
www.bcbsm.comICD-10ProviderReadiness@bcbsm.com Page 1 of 2 Mental and Behavioral Health ICD-10-CM Coding Tip Sheet Overview of Key Chapter 5 Updates for Mental, Behavioral and
Frequently Asked Questions - bcbsm.com
www.bcbsm.comclaims faster, and it can reduce your out-of coverage information. If you don’t have other coverage, please indicate that on the form and return it to us.
Medicare Advantage Enhanced Benefits - bcbsm.com
www.bcbsm.comBlue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association. BCBSM Medicare Advantage – Enhanced Benefits Fee Schedule Page 2 of 9 Revised 11/30/17
Your Benefit Guide - Blue Cross Blue Shield of …
www.bcbsm.comYour Benefit Guide Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association.
Required Document Reference List - bcbsm.com
www.bcbsm.com(enrolling a new practitioner not already affiliated with BCBSM/BCN and adding them to the Group) The following documents are required to enroll the new Practitioner (this section is only applicable for a small number of pr ovider types):
Deciding whether to appeal a clinical editing denial
www.bcbsm.com1 Appealing a clinical editing denial For Blue Cross Medicare Plus BlueSM PPO December 2017 Deciding whether to appeal a clinical editing denial When you’re deciding whether to appeal a clinical editing denial, here’s what you should know: • There’s only one level of appeal.
What is CAQH? - bcbsm.com
www.bcbsm.comThe Council for Affordable Quality Healthcare® (CAQH) is a not-for-profit collaborative alliance of the nation's leading health plans and networks. CAQH's mission is the improvement of healthcare access and quality for patients and the
Related documents
IMHA disease in canines – diagnosis and treatment
www.vettimes.co.ukA mild thrombocytopenia may indicate secondary thromboembolic disease. A severe thrombocytopenia is consistent with Evans syndrome, where the platelets are also targeted by the immune system. Serum biochemistry is usually normal or shows changes secondary to dehydration and/or tissue
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eudisease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment ... Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have
Lists of medicinal products for rare diseases in Europe*
www.orpha.netChronic thromboembolic pulmonary hypertension (CTEPH), persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. As monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euVenous thromboembolic events were reported in 5.3% of patients treated with abemaciclib plus fulvestrant or aromatase inhibitors, compared to 0.8% of patients treated with placebo plus fulvestrant or aromatase inhibitors. Patients should be monitored for signs and symptoms of deep vein thrombosis